Joseph Thaddeus Beck
Impact in
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
- Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies
Papers in
- Oncology 47
- Lung Cancer Research Studies 11
- HER2/EGFR in Cancer Research 10
- Cancer Treatment and Pharmacology 9
- Colorectal Cancer Treatments and Studies 8
- Cancer Immunotherapy and Biomarkers 7
-
- Advanced Breast Cancer Therapies 29
- Lung Cancer Treatments and Mutations 10
- Co-authors
- Paolo A. Ascierto (3 shared papers)Angela Zubel (3 shared papers)Dirk Schadendorf (3 shared papers)John A. Hohneker (2 shared papers)Adam M. Brufsky (2 shared papers)C. W. Seidler (2 shared papers)Paola Queirolo (3 shared papers)Sanjiv S. Agarwala (3 shared papers)
- Journals
- Annals of Oncology (20 papers)Journal of Clinical Oncology (8 papers)Clinical Cancer Research (6 papers)The Lancet Oncology (5 papers)Oncotarget (4 papers)
- Partner nations
- United StatesSwitzerlandItaly
In The Last Decade
Joseph Thaddeus Beck
102 papers receiving 10.0k citations
Joseph Thaddeus Beck's Hit Papers
Peers
Comparison fields: 5 of 117
- Oncology 4.9k
- Pulmonary and Respiratory Medicine 4.3k
- Cancer Research 1.8k
- Genetics 659
- Pathology and Forensic Medicine 661
Countries citing papers authored by Joseph Thaddeus Beck
This map shows the geographic impact of Joseph Thaddeus Beck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Thaddeus Beck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Thaddeus Beck more than expected).
Fields of papers citing papers by Joseph Thaddeus Beck
This network shows the impact of papers produced by Joseph Thaddeus Beck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Thaddeus Beck. The network helps show where Joseph Thaddeus Beck may publish in the future.
Co-authors
The 25 scholars most cited alongside Joseph Thaddeus Beck, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 107 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2011 | 2395 |
| 2 | Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 Hit paper breakdown → | 2018 | 868 |
| 3 | Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer Hit paper breakdown → | 2019 | 606 |
| 4 | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study Hit paper breakdown → | 2013 | 555 |
| 5 | Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years Hit paper breakdown → | 2016 | 499 |
| 6 | Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Hit paper breakdown → | 2019 | 374 |
| 7 | Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2014 | 356 |
| 8 | 1994 | 293 | |
| 9 | 2016 | 282 | |
| 10 | 2006 | 257 | |
| 11 | 2015 | 250 | |
| 12 | 2019 | 241 | |
| 13 | Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival Hit paper breakdown → | 2021 | 200 |
| 14 | 2017 | 184 | |
| 15 | 2015 | 174 | |
| 16 | 2011 | 160 | |
| 17 | 2014 | 135 | |
| 18 | 2014 | 117 | |
| 19 | 2016 | 115 | |
| 20 | 2014 | 104 |
About Joseph Thaddeus Beck
Joseph Thaddeus Beck is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Genetics and Molecular Biology, having authored 107 papers that have together received 10.3k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (29 papers), Lung Cancer Research Studies (11 papers), HER2/EGFR in Cancer Research (10 papers), Lung Cancer Treatments and Mutations (10 papers), Cancer Treatment and Pharmacology (9 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). The work is most often cited by research in Oncology (4.9k citations), Pulmonary and Respiratory Medicine (4.3k citations), Cancer Research (1.8k citations), Genetics (659 citations) and Pathology and Forensic Medicine (661 citations). Joseph Thaddeus Beck has collaborated with scholars based in United States, Switzerland and Italy. Frequent co-authors include Paolo A. Ascierto, Angela Zubel, Dirk Schadendorf, John A. Hohneker, Adam M. Brufsky, C. W. Seidler, Paola Queirolo, Sanjiv S. Agarwala, W. Graydon Harker and Edith A. Perez. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research, The Lancet Oncology and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.